Prognostic value of MYBL2 and its potential implications for immunotherapy: a study of bioinformatics and experimental validation.

BACKGROUND: MYBL2, a member of the MYB transcription factor family, promotes the advancement of certain types of malignancies. However, the involvement of MYBL2 in endometrial cancer (EC) remains uncertain, and its investigation at the pan-cancer level is ongoing. METHODS: In order to conduct an analysis and visualisation of The Cancer Genome Atlas and Genotype-Tissue Expression databases, along with transcriptomic data, we employed the use of R software and various online tools. Additionally, the effects of MYBL2 downregulation on the functional capabilities of EC cells were investigated using a range of methods, including the CCK8 assay, Transwell assay, flow cytometry assay, and western blot analysis. Furthermore, the expression of MYBL2 was evaluated in clinical EC tissues and tumour sections of nude mice through the utilisation of an immunohistochemical assay. RESULTS: We identified MYBL2 as a potential target for the impact of icariside II on EC progression. Meanwhile, we successfully developed a prognostic model for MYBL2 expression in patients with EC. Moreover, a notable decrease in EC cell growth and migration was observed when MYBL2 expression was suppressed. Our pan-cancer examination revealed that MYBL2 was significantly upregulated in most malignancies and was associated with poor prognosis in these cases. Moreover, there was an important connection between high MYBL2 expression and immune cell infiltration as well as immune checkpoint genes. CONCLUSIONS: These outcomes emphasise the notable relationship between cancer progression and the expression of MYBL2, indicating that MYBL2 could function as a potential biomarker for the prognosis and immunotherapy of malignancies. These results provide a new perspective for cancer treatment, particularly for EC.